Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Calcium chloride dihydrate, Potassium chloride, Sodium chloride, Sodium lactate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
Compound Sodium Lactate Infusion How you will be given Compound Sodium Lactate Infusion Possible side effects How to store Compound Sodium Lactate Infusion Contents of the pack and other information
You must NOT receive Compound Sodium Lactate Infusion if you are suffering from any of the following conditions • •
•
This medicine is called "Compound Sodium Lactate Solution for Infusion BP", but will be referred to as "Compound Sodium Lactate Infusion" throughout the document.
• •
1. What Compound Sodium Lactate Infusion Is and What It Is Used For
•
Compound Sodium Lactate Infusion is a solution of the following substances in water:
•
Sodium, potassium, calcium, chloride and lactate are chemical substances (electrolytes) found in the blood.
•
•
• • 1
if you're a newborn (less than 28 days old) receiving ceftriaxone (an antibiotic) if you're allergic to sodium lactate or any of the other ingredients in Compound Sodium Lactate (listed in section 6) when there is too much fluid in the spaces around the cells of the body (extracellular hyperhydration) when there is a larger volume of blood in the blood vessels than there should be (hypervolaemia) severe kidney failure (when your kidneys do not work well and you require dialysis) uncompensated heart failure. This is heart failure that is not adequately treated and causes symptoms such as:
• •
• •
a particular type of metabolic acidosis (lactic acidosis) severe liver disease (when the liver does not function properly and requires very intensive treatment) poor lactate metabolism (this occurs in severe liver disease, as lactate is removed by the liver) if you are taking cardiac glycosides (cardiotonics) used to treat heart failure, such as digitalis or digoxin (see also "Taking other medicines")
•
• • • •
Warning and precautions Talk to your doctor or nurse before receiving Compound Sodium Lactate Infusion if you have or have had any of the following medical conditions: • if you're receiving ceftriaxone (an antibiotic) (see also "Other medicines and Compound Sodium Lactate Infusion")
diseases associated with high levels of vitamin D (e.g. sarcoidosis, a disease affecting the skin and internal organs) kidney stones poor liver function diabetes if you have a condition that could cause high levels of vasopressin, a hormone regulating fluid in your body. You may have too much vasopressin in your body because, for example:
This may increase the risk of low levels of sodium in your blood and can lead to headache, nausea, seizures, lethargy, coma, swelling of the brain and death. Brain swelling increases the risk of death and brain damage. People who are at higher risk of brain swelling are:
TH-30-02-186
As Compound Sodium Lactate Infusion contains lactate (a substance found in the body), it can make your blood too alkaline (metabolic alkalosis).
• • •
Compound Sodium Lactate Infusion should be given with special care to babies less than 6 months of age. Your doctor will take into account if you are receiving parenteral nutrition (nutrition given by infusion into a vein). If you are given Compound Sodium Lactate Infusion for a long time, you will be given an extra source of nutrients.
• • • •
Other medicines and Compound Sodium Lactate Infusion
•
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. It is particularly important that you inform your doctor if you are taking:
• •
anti-diabetic medication (chlorpropamide) cholesterol medicine (clofibrate) some cancer drugs (vincristine, ifosfamide, cyclophosphamide) selective serotonin reuptake inhibitors (used to treat depression) antipsychotics opioids for severe pain relief medicines for pain and/or inflammation (also known as NSAIDs) medicines that imitate or strengthen the effects of vasopressin such as desmopressin (used to treat increased thirst and urination), terlipressin (used to treat bleeding of the gullet) and oxytocin (used to induce labour) anti-epileptic medication (carbamazepine and oxcarbazepine) diuretics (water tablets).
Other medicines that can affect or be affected by Compound Sodium Lactate Infusion include:
The following medicines can increase the concentration of potassium in the blood. This effect can be life-threatening. A rise in the blood potassium levels is more likely to occur if you have kidney disease.
Compound Sodium Lactate Infusion with food and drink You should ask your doctor about what you can eat or drink.
Pregnancy, breast-feeding and fertility If you are pregnant of breast feeding, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before taking this medicine.
Some medicines act on the hormone vasopressin. These may include: 3
TH-30-02-186
Compound Sodium Lactate Infusion can be used safely during pregnancy or breast-feeding. Your doctor will monitor the levels of chemicals in your blood and the amount of fluid in your body.
•
Calcium can reach your unborn baby through the placenta and, after birth, through the breast milk. However, if another medicine is to be added to your solution for infusion during pregnancy or breast-feeding you should:
Driving and using machines Ask your doctor or pharmacist for advice before driving or using machines.
Compound Sodium Lactate Infusion You will be given Compound Sodium Lactate Infusion by a doctor or nurse. Your doctor will decide on how much you need and when it is to be given. This will depend on your age, weight, condition and the reason for treatment. The amount you are given may also be affected by other treatments you are receiving.
You should NOT be given Compound Sodium Lactate Infusion if there are particles floating in the solution or if the pack is damaged in any way. Compound Sodium Lactate Infusion will usually be given to you through a plastic tube attached to a needle in a vein. Usually a vein in your arm is used to give you the infusion. However, your doctor may use another method to give you the medicine.
•
Before and during the infusion, your doctor will monitor:
liquid in the tissues (oedema) causing swelling hyperkalaemia (higher levels of potassium in the blood than normal) especially in patients with kidney failure, causing symptoms such as:
If you develop any of these symptoms you must inform your doctor immediately. Your infusion will be stopped and you will be given treatment depending on the symptoms.
If you receive more Compound Sodium Lactate Infusion than you should If you are given too much Compound Sodium Lactate Infusion (over-infusion) or it is given too fast, this may lead to the following symptoms:
If a medicine has been added to your Compound Sodium Lactate Infusion before over-infusion occurs, that medicine may also cause symptoms. You should read the Package Leaflet of the added medicine for a list of possible symptoms. TH-30-02-186
Stopping your Compound Sodium Lactate Infusion
• •
Your doctor will decide when to stop giving you this infusion. If you have any further questions on the use of this product, ask your doctor or nurse.
•
local pain or reaction redness or swelling at the site of infusion irritation and inflammation of the vein into which the solution is infused (phlebitis). This can cause redness, pain or burning and swelling along the path of the vein into which the solution is infused. rash or itching (pruritus) of the infusion site.
Other side effects noted with similar products (other sodium-lactate containing solutions) include:
4. Possible Side Effects Like all medicines, this medicine can cause side effects, although not everybody gets them. If you have any of the following symptoms you should tell your doctor or nurse immediately. These may be signs of a very severe or even fatal hypersensitivity (allergic) reaction called anaphylactic shock:
If a medicine has been added to the solution for infusion, the added medicine may also cause side effects. These
will depend on the medicine that has been added. You should read the Package Leaflet of the added medicine for a list of possible symptoms.
Reporting of side effects If you get any side effect, talk to your doctor or nurse. This includes any possible side effect not listed in this leaflet. Ireland: You can also report side effects directly via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie Email: [email protected]. UK: You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard Malta Website: www.medicinesauthority.gov.mt/adrportal
Higher levels of potassium in the blood than normal (hyperkalaemia)
By reporting side effects, you can help provide more information on the safety of this medicine.
Low levels of sodium in the blood that may be acquired during hospitalization (nosocomial hyponatraemia) and related neurological disorder (acute hyponatraemic encephalopathy). Hyponatraemia can lead to irreversible brain injury and death due to cerebral oedema/swelling (see also section 2 "Warnings and precautions").
Compound Sodium Lactate Infusion
Reactions due to the administration technique manifested by one or more of the following symptoms:
Keep this medicine out of the sight and reach of children. 5
TH-30-02-186
Marketing Authorisation Holder and Manufacturers
250 ml bags: Do not store above 30 °C. 500 ml and 1000 ml bags do not require special storage conditions.
Marketing Authorisation Holder:
Compound Sodium Lactate Infusion should NOT be given to you after the expiry date which is stated on the bag after EXP: MM/YYYY. The expiry date refers to the last day of that month.
United Kingdom Baxter Healthcare Ltd Caxton Way, Thetford, Norfolk, IP24 3SE United Kingdom Ireland and Malta Baxter Holding B.V. Kobaltweg 49, 3542CE Utrecht, Netherlands
You should not be given Compound Sodium Lactate Infusion, if there are particles floating in the solution or if the unit is damaged in any way.
Manufacturers for Great Britian:
What Compound Sodium Lactate Infusion contains
Baxter SA Boulevard René Branquart, 80 7860 Lessines Belgium Baxter Healthcare Ltd. Caxton Way, Thetford Norfolk IP24 3SE United Kingdom Bieffe Medital S.A. Ctra de Biescas, Senegüé 22666 Sabiñanigo (Huesca) Spain
The active substances are:
What Compound Sodium Lactate Infusion looks like and contents of the pack
Manufacturers for Ireland and Malta: Baxter SA Boulevard René Branquart, 80 7860 Lessines Belgium Bieffe Medital S.A. Ctra de Biescas, Senegüé 22666 Sabiñanigo (Huesca) Spain
Compound Sodium Lactate Infusion is a clear solution, free from visible particles. It is supplied in polyolefin/ polyamide plastic bags (Viaflo). Each bag is wrapped in a sealed, protective, outer plastic overpouch. The bag sizes are:
This leaflet was last revised in June 2023
Pack sizes:
For Information about Compound Sodium Lactate Infusion or to request this leaflet in formats such as audio or large print please contact the Marketing Authorisation Holder: Tel: +44 (0)1635 206345.
Not all pack sizes may be marketed
Baxter and Viaflo are trademarks of Baxter International lnc.
6
TH-30-02-186
Compound Sodium Lactate Solution for Infusion BP The following information is intended for healthcare professionals only:
b.
Handling and Preparation
c.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not administer unless the solution is clear and the seal is intact. Do not remove unit from overwrap until ready for use. The inner bag maintains the sterility of the product. Administer immediately following the insertion of infusion set. Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is completed. Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration. Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers. The solution is for intravenous administration through a sterile administration set using aseptic technique. The equipment should be primed with the solution in order to prevent air entering the system. Additives may be introduced before infusion or during infusion through the injection site. When additive is used, verify isotonicity prior to parenteral administration. Thorough and careful aseptic mixing of any additive is mandatory. Solutions containing additives should be used immediately and not stored. Adding other medication or using an incorrect administration technique might cause the appearance of fever reactions due to the possible introduction of pyrogens. In case of adverse reaction, infusion must be stopped immediately. Discard after single use. Discard any unused portion. Do not reconnect partially used bags.
2. Preparation for administration Use sterile material for preparation and administration. a. Suspend container from eyelet support. b. Remove plastic protector from outlet port at bottom of container:
3. Techniques for injection of additive medications Warning: Additives may be incompatible Check additive compatibility with both the solution and container prior to use. When additive is used, verify isotonicity prior to parenteral administration. (See Paragraph 5 "Incompatibilities of additive medications" below). To add medication before administration a. Disinfect medication port. b. Using syringe with 19 gauge (1.10 mm) to 22 gauge (0.70 mm) needle, puncture re-sealable medication port and inject. c. Mix solution and medication thoroughly. For high-density medication such as potassium chloride, tap the ports gently while ports are upright and mix. Caution: Do not store bags containing added medications. To add medication during administration a. Close clamp on the set. b. Disinfect medication port.
1. Opening a.
Remove the Viaflo container from the overpouch just before use.
Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution, as sterility may be impaired. Check the solution for clarity and absence of foreign matters. If solution is not clear or contains foreign matters, discard the solution.
7
TH-30-02-186
c.
d. e. f. g.
Using syringe with 19 gauge (1.10 mm) to 22 gauge (0.70 mm) needle, puncture re-sealable medication port and inject. Remove container from IV pole and/or turn to an upright position. Evacuate both ports by tapping gently while the container is in an upright position. Mix solution and medication thoroughly. Return container to in use position, re-open the clamp and continue administration.
•
4. In-use shelf-life: Additives The chemical and physical stability of any additive at the pH of Compound Sodium Lactate Infusion in the Viaflo container should be established prior to use. From a microbiological point of view, the diluted product must be used immediately unless dilution has taken place in controlled and validated aseptic conditions. If not used immediately, in-use storage times and conditions are the responsibility of the user.
− Diethylstilbestrol − Etamivan − Ethyl alcohol − Phosphate and carbonate solutions − Oxytetracycline − Thiopental sodium − Versenate disodium Medications with partial incompatibility with Compound Sodium Lactate Solution: − Tetracycline stable for 12 hours − Ampicillin sodium concentration of 2%-3% stable for 4 hours concentration >3% must be given within 1 hour − Minocycline stable for 12 hours − Doxycycline stable for 6 hours
Those additives known to be incompatible should not be used.
5. Incompatibilities of additive medications Ceftriaxone must not be mixed with calcium-containing solutions including Compound Sodium Lactate Infusion. As with all parenteral solutions additives may be incompatible. Compatibility of the additives with the Compound Sodium Lactate Infusion must be assessed before addition. After addition of the additive, incompatibility may become visible by a possible colour change and/or the appearance of precipitates, insoluble complexes or crystals. The Instructions for Use of the medication to be added and other relevant literature must be consulted. Before adding a substance or medication, verify it is soluble and/or stable in water at the pH range of Compound Sodium Lactate Infusion (pH 5.0 to 7.0). When making additions to Compound Sodium Lactate Infusion aseptic technique must be used. Mix the solution thoroughly when additives have been introduced. Do not store solutions containing additives. As guidance the following medications are incompatible with the Compound Sodium Lactate Infusion (non-exhaustive listing):
Baxter and Viaflo are trademarks of Baxter International lnc.
8
TH-30-02-186
Compound Sodium Lactate Solution for Infusion BP comes as infusion. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Compound Sodium Lactate Solution for Infusion BP is calcium chloride dihydrate, potassium chloride, sodium chloride, sodium lactate.
Medicines with the same active substance, strength and form include: Hartmann's Solution Compound Sodium Lactate Intravenous Infusion BP. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Compound Sodium Lactate Solution for Infusion BP, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Compound Sodium Lactate solution is used in the following indications:
- Restoration of extracellular fluid and electrolytes balances or replacement of extracellular fluid loss where isotonic concentrations of electrolytes are sufficient
- Short term volume replacement (alone or in association with colloid) in case of hypovolaemia or hypotension.
- Regulation or maintenance of metabolic acidosis balance and/or treatment of mild to moderate metabolic acidosis (except lactic acidosis)
Posology
Adults, the Elderly and Children:
Fluid balance, serum electrolytes and acid-base balance should be monitored before and during administration, with particular attention to serum sodium in patients with increased non-osmotic vasopressin release (syndrome of inappropriate antidiuretic hormone secretion, SIADH) and in patients co-medicated with vasopressin agonist drugs, due to the risk of hospital acquired hyponatraemia (see sections 4.4, 4.5 and 4.8). Monitoring of serum sodium is particularly important for hypotonic fluids.
Compound Sodium Lactate solution has a tonicity of 278 mOsm/l (approx.)
The infusion rate and volume depend on the age, weight, clinical condition (e.g. burns, surgery, head-injury, infections), and concomitant therapy should be determined by the consulting physician experienced in intravenous fluid therapy (see sections 4.4. and 4.8).
Recommended dosage:
The amount of Compound Sodium Lactate solution needed to restore normal blood volume is 3 to 5 times the volume of lost blood.
The recommended dosage is:
- for adults: 500 ml to 3 L/24h
- for infants, toddlers and children: 20 ml to 100 ml/kg/24 h
Administration rate:
The infusion rate is usually 40 mL/kg/24h in adults.
Use in paediatric patients
The safety and efficacy of Compound Sodium Lactate solution in children has not been established by adequate and well-controlled trials; however, the use of electrolyte solutions in the paediatric population is referenced in the medical literature. Lactate-containing solutions should be administered with particular caution to neonates and infants less than 6 months of age.
Paediatric infusion rates is 5 ml/kg/h in average but the value varies with age:
• infants: 6-8 mL/kg/h,
• toddlers: 4-6 mL/kg/h
• children: 2-4 mL/kg/h .
In children with burns, the dose is on average 3.4 mL/kg/per cent burn at 24 h post-burn and 6.3 mL/kg/per cent burn at 48 h.
In severely head-injured children the dose is on average 2850 mL/m2.
Infusion rate and total volume can be higher in surgery or in case of need.
Note:
- infants and toddlers: aged from 28 days to 23 months (a toddler is an infant who can walk)
- children: age from 2 to 11 years
Use in geriatric patients
When selecting the type of infusion solution and the volume/rate of infusion for a geriatric patient, consider that geriatric patients are generally more likely to have cardiac, renal, hepatic, and other diseases or concomitant drug therapy.
Method of administration:
The solution is for intravenous administration through a sterile and non-pyrogenic administration set using aseptic technique. The equipment should be primed with the solution in order to prevent air entering the system.
The solution should be inspected visually for particulate matter and discoloration prior to administration. Do not administer unless the solution is clear, free from visible particles and the seal is intact. Do not remove unit from overwrap until ready for use. The inner bag maintains the sterility of the solution. Administer immediately following the insertion of infusion set.
Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container. Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration. Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.
Additives may be introduced before infusion or during infusion through the injection site. When making additions to Compound Sodium Lactate solution, aseptic technique must be used. Mix the solution thoroughly when additives have been introduced. Do not store solutions containing additives.
For information on incompatibilities and preparation of the product with additives, please see sections 6.2 and 6.6.
As for other calcium-containing infusion solutions, concomitant administration of ceftriaxone and Compound Sodium Lactate solution is contraindicated in newborns (≤28 days of age), even if separate infusion lines are used (risk of fatal ceftriaxone-calcium salt precipitation in the neonate's bloodstream). For patients over 28 days of age please see section 4.4.
Compound Sodium Lactate solution is also contraindicated in patients with
• A known hypersensitivity to sodium lactate.
• Extracellular hyperhydration or hypervolaemia
• Severe renal insufficiency (with oliguria/anuria)
• Uncompensated cardiac failure
• Hyperkalaemia
• Hypercalcaemia
• Metabolic alkalosis
• Ascitic cirrhosis
• Severe metabolic acidosis
• Conditions associated with increased lactate levels (hyperlactataemia) including lactic acidosis, or impaired lactate utilization, such as severe hepatic insufficiency.
• Concomitant digitalis therapy (see section 4.5 Interactions with other medicinal products and other forms of interaction)
Hypersensitivity reactions
The infusion must be stopped immediately if any signs or symptoms of a suspected hypersensitivity reaction develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.
Incompatibilities
Ceftriaxone
In patients older than 28 days (including adults), ceftriaxone must not be administered simultaneously with intravenous calcium-containing solutions, including Compound Sodium Lactate solution, through the same infusion line. If the same infusion line is used for sequential administration, the line must be thoroughly flushed between infusions with a compatible fluid. For patients under 28 days please see section 4.3.
Electrolyte balance
Hypernatraemia
Compound Sodium Lactate solution should only be administered to patients with hypernatraemia after careful consideration of the underlying cause and alternative intravenous fluids. Monitoring of plasma sodium and volume status during treatment is recommended.
Compound Sodium Lactate solution should be administered with particular caution in patients with conditions predisposing to hypernatraemia (such as adrenocortical insufficiency, diabetes insipidus or extensive tissue injury) and in patients with cardiac disease.
Hyperchloraemia
Compound Sodium Lactate solution should only be administered to patients with hyperchloraemia after careful consideration of the underlying cause and alternative intravenous fluids. Monitoring of plasma chloride and acid-base balance during treatment is recommended.
Compound Sodium Lactate solution should be administered with particular caution to patients with conditions predisposing to hyperchloraemia (such as renal failure and renal tubular acidosis, diabetes insipidus), and patients with urinary diversion or patients taking certain diuretics (carbonic anhydrase inhibitors eg acetazolamide) or steroids (androgens, estrogens corticosteroids) and in patients with severe dehydration.
Use in patients with potassium deficiency
Although Compound Sodium Lactate solution has a potassium concentration similar to the concentration in plasma, it is insufficient to produce a useful effect in case of severe potassium insufficiency and therefore it should not be used for this purpose.
Use in patients at risk for hyperkalaemia
Compound Sodium Lactate solution should be administered with particular caution to patients with conditions predisposing to hyperkalaemia (such as severe renal impairment or adrenocortical insufficiency, acute dehydration, or extensive tissue injury or burns) and in patients with cardiac disease. The plasma potassium level of the patient must be particularly closely monitored in patients at risk of hyperkalaemia.
Use in patients at risk for hypercalcaemia
Calcium chloride is irritant, therefore care should be taken to prevent extravasation during intravenous injection and intramuscular injection must be avoided. Solutions containing calcium salts should be used with caution in patients with conditions predisposing to hypercalcaemia, such as patients with renal impairment and granulomatous diseases associated with increased calcitriol synthesis such as sarcoidosis, calcium renal calculi or a history of such calculi.
Fluid balance/renal function
Use in patients with renal impairment
Compound Sodium Lactate solution should be administered with particular caution to patients with renal impairment. In such patients administration of Compound Sodium Lactate solution may result in sodium and/or potassium retention.
Risk of Fluid and/or Solute Overload and Electrolyte Disturbances
Depending on the volume and rate of infusion, intravenous administration of Compound Sodium Lactate solution can cause
• fluid and/or solute overload resulting in overhydration and, for example, congested states, including pulmonary congestion and oedema.
• clinically relevant electrolyte disturbances and acid-base imbalance.
Clinical evaluation and periodic laboratory determinations may be necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.
High volume infusion must be used under specific monitoring in patients with cardiac or pulmonary failure and in patients with non-osmotic vasopressin release (including SIADH), due to the risk of hospital-acquired hyponatraemia (see below).
Hyponatraemia
Patients with non-osmotic vasopressin release (e.g. in acute illness, pain, post-operative stress, infections, burns, and CNS diseases), patients with heart-, liver- and kidney diseases and patients exposed to vasopressin agonists (see section 4.5) are at particular risk of acute hyponatraemia upon infusion of hypotonic fluids.
Acute hyponatraemia can lead to acute hyponatraemic encephalopathy (cerebral oedema) characterized by headache, nausea, seizures, lethargy and vomiting. Patients with cerebral oedema are at particular risk of severe, irreversible and life-threatening brain injury.
Children, women in the fertile age and patients with reduced cerebral compliance (e.g. meningitis, intracranial bleeding, cerebral contusion and brain oedema) are at particular risk of the severe and life-threatening brain swelling caused by acute hyponatraemia.
Use in patients with hypervolaemia, overhydration or conditions causing sodium retention and oedema
Compound Sodium Lactate solution should be administered with particular caution to hypervolaemic or overhydrated patients.
Due to the sodium chloride content Compound Sodium Lactate solution should be administered with particular caution to patients with conditions that may cause sodium retention, fluid overload and oedema, such as patients with primary hyperaldosteronism, secondary hyperaldosteronism (associated with, e.g., hypertension, congestive heart failure, renal artery stenosis, or nephrosclerosis), or preeclampsia. (see also Section 4.5)
Acid-base balance
Use in patients at risk for alkalosis
Compound Sodium Lactate solution should be administered with particular caution to patients at risk for alkalosis. Because lactate is metabolized to bicarbonate, administration may result in, or worsen, metabolic alkalosis. Seizure may be precipitated by the alkalosis induced by lactate but this is uncommon.
Other warnings
Administration of citrate anticoagulated/preserved blood
Due to the risk of coagulation precipitated by its calcium content, Compound Sodium Lactate solution must not be added to or administered simultaneously through the same tubing with citrate anticoagulated/preserved blood.
Use in patients with type 2 diabetes
Lactate is a substrate for gluconeogenesis. Therefore, glucose levels should be carefully monitored in patients receiving Compound Sodium Lactate.
Administration
Adding other medication or using an incorrect administration technique might cause the appearance of fever reactions due to the possible introduction of pyrogens. In such case the infusion must be stopped immediately.
For information on incompatibilities and preparation of the product with additives, please see sections 6.2 and 6.6.
During long term parenteral treatment, a convenient nutritive supply must be given to the patient.
Ceftriaxone: See sections 4.3 and 4.4 for more information
Drugs leading to an increased vasopressin effect
The below listed drugs increase the vasopressin effect, leading to reduced renal electrolyte free water excretion and may increase the risk of hospital acquired hyponatraemia following inappropriately balanced treatment with i.v. fluids (see sections 4.2, 4.4 and 4.8).
• Drugs stimulating vasopressin release include: Chlorpropamide, clofibrate, carbamazepine, vincristine, selective serotonin reuptake inhibitors, 3.4-methylenedioxy-N-methamphetamine, ifosfamide, antipsychotics, narcotics
• Drugs potentiating vasopressin action include: Chlorpropamide, NSAIDs, cyclophosphamide
• Vasopressin analogues include: Desmopressin, oxytocin, terlipressin
Other medicinal products increasing the risk of hyponatraemia also include diuretics in general and antiepileptics such as oxcarbazepine.
Interaction related to the presence of sodium:
Caution is advised when administering Compound Sodium Lactate solution to patients treated with drugs that may increase the risk of sodium and fluid retention (with oedema and hypertension), such as corticosteroids.
Interaction related to the presence of potassium:
Because of its potassium content, Compound Sodium Lactate solution should be administered with caution in patients treated with agents or products that can cause hyperkalaemia or increase the risk of hyperkalaemia, such as
- Potassium-sparing diuretics (amiloride, spironolactone, triamterene, alone or in association).
- Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists
- Tacrolimus, cyclosporine
Administration of potassium in patients treated with such medications can produce severe and potentially fatal hyperkalaemia, particularly in patients with severe renal insufficiency.
Interaction related to the presence of calcium:
Administration of calcium may increase the effects of digitalis and lead to serious or fatal cardiac arrhythmia. Therefore, larger volumes or a faster infusion rates should be used with caution in patients treated with digitalis glycosides.
- Caution is advised when administering Compound Sodium Lactate solution to patients treated with thiazide diuretics or vitamin D, as these can increase the risk of hypercalcaemia.
- Bisphosphonates, fluoride, some fluoroquinolones and tetracyclines which are less absorbed (lower availability) when administered with calcium.
Interaction related to the presence of lactate (which is metabolized into bicarbonate):
Caution is advised when administering Compound Sodium Lactate solution to patients treated with drugs for which renal elimination is pH dependent. Due to the alkalinizing action of lactate (formation of bicarbonate), Compound Sodium Lactate solution may interfere with the elimination of such drugs.
- Renal clearance of acidic drugs such as salicylates, barbiturates, and lithium may be increased because of the alkalinisation of urine by the bicarbonate resulting from lactate metabolism.
- Renal clearance of alkaline drugs, such as sympathomimetics (e.g. ephedrine, pseudoephedrine) and stimulants (e.g. dexamphetamine sulfate, phenfluramine hydrochloride) may be decreased
Compound Sodium Lactate solution can be used safely during pregnancy and lactation as long as the electrolyte- and fluid balance is controlled.
It is reminded that calcium crosses the placenta and is distributed into breast milk.
Compound Sodium Lactate solution should be administrated with special caution for pregnant women during labour particularly as to serum-sodium if administered in combination with oxytocin (see section 4.4, 4.5 and 4.8).
When a medication is added, the nature of the drug and its use during pregnancy and lactation have to be considered separately.
There is no information of the effects of Compound Sodium Lactate solution on the ability to operate an automobile or other heavy machinery.
The following adverse reactions (listed by MedDRA System Organ Class) have been reported spontaneously during the post-market experience.
Immune System Disorders
Hypersensitivity/Infusion reactions including Anaphylactic/Anaphylactoid reaction, possibly manifested by one or more of the following symptoms: Angioedema, Chest pain, Chest discomfort, Decreased heart rate, Tachycardia, Blood pressure decreased, Respiratory distress, Bronchospasm, Dyspnea, Cough, Urticaria, Rash, Pruritus, Erythema, Flushing, Throat irritation, Paresthesias, Hypoesthesia oral, Dysgeusia, Nausea, Anxiety, Pyrexia, Headache
Metabolism and Nutrition Disorders
Hyperkalaemia
Hospital acquired hyponatraemia*
Nervous system disorders
Acute hyponatraemic encephalopathy*
General Disorders and Administration Site Conditions
Infusion Site Reactions manifested by one or more of the following symptoms: Phlebitis, Infusion site inflammation, Infusion site swelling, Infusion site rash, Infusion site pruritus, Infusion site erythema, Infusion site pain, Infusion site burning
*Hospital acquired hyponatraemia may cause irreversible brain injury and death, due to development of acute hyponatraemic encephalopathy, frequency unknown (see sections 4.2. 4.4, 4.5).
The following adverse reactions have been reported spontaneously during the use of other sodium-lactate containing solutions:
• Hypersensitivity: Laryngeal oedema (Quincke's oedema), skin swelling, Nasal congestion, Sneezing
• Electrolyte disturbances
• Hypervolaemia
• Panic Attack
• Other infusion site reactions: Infection at the site of injection, Extravasation, Infusion site anesthesia (numbness)
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.
Website: www.mhra.gov.uk/yellowcard
An excessive volume or too high a rate of administration of Compound Sodium Lactate solution may lead to fluid and sodium overload with a risk of oedema (peripheral and/or pulmonary), particularly when renal sodium excretion is impaired. In this case extra renal dialysis may be necessary.
Excessive administration of potassium may lead to the development of hyperkalaemia, especially in patients with renal impairment. Symptoms include paresthesia of the extremities, muscle weakness, paralysis, cardiac arrhythmias, heart block, cardiac arrest, and mental confusion.
Excessive administration of calcium salts may lead to hypercalcaemia. Symptoms of hypercalcaemia may include anorexia, nausea, vomiting, constipation, abdominal pain, muscle weakness, mental disturbances, polydipsia, polyuria, nephrocalcinosis, renal calculi, and, in severe cases, cardiac arrhythmias and coma. Too rapid intravenous injection of calcium salts may also lead to many of the symptoms of hypercalcaemia as well as to chalky taste, hot flushes, and peripheral vasodilatation. Mild asymptomatic hypercalcaemia will usually resolve on stopping administration of calcium and other contributory drugs such as vitamin D. If hypercalcaemia is severe, urgent treatment (such as loop diuretics, haemodialysis, calcitonin, bisphosphonates, trisodium edetate) is required.
Excessive administration of lactate may lead to metabolic alkalosis. Metabolic alkalosis may be accompanied by hypokalaemia, Symptoms may include mood changes, tiredness, shortness of breath, muscle weakness, and irregular heartbeat. Muscle hypertonicity, twitching, and tetany may develop especially in hypocalcaemic patients. Treatment of metabolic alkalosis due to bicarbonate overdose consists mainly of appropriate correction of fluid and electrolyte balance. Replacement of calcium, chloride, and potassium may be of particular importance.
When overdose is related to medications added to the solution infused, the signs and symptoms of over infusion will be related to the nature of the additive being used. In the event of accidental over infusion, treatment should be discontinued and the patient should be observed for the appropriate signs and symptoms related to the drug administered. The relevant symptomatic and supportive measures should be provided as necessary.
Ask anything about Compound Sodium Lactate Solution for Infusion BP. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.